PCSK9 and familial hypercholesterolemia: Current lipid-lowering agents such as ezetimibe, PCSK9 inhibitors, BDA, and inclisiran are used in treating hypercholesterolemia as monotherapy or combination concerning safety, efficacy, and Cardiovascular benefits.